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ABSTRACT 
Objective: Owing to the continuous evolution of antibiotic resistance, treatment with natural products represents significant adjuncts or 
alternatives to conventional antibiotic therapy. Enterobacteriaceae especially Escherichia coli have acquired antibiotic resistance due to production 
of Extended spectrum Beta-lactamases (ESBL).  
Methods: Effect of Aqueous extract of Green tea (AGTE) was studied on 44 ESBL producing, diarrhea causing E. coli. ESBL production of the strains 
was confirmed by phenotypic confirmatory disc diffusion test (PCDDT) and E-test. Antibacterial activity of AGTE was studied by disc diffusion 
method and the Minimum Inhibitory Concentration (MIC) of AGTE and Cefotaxime were determined by an agar dilution technique. The combined 
activity of AGTE and Cefotaxime was determined by calculating the fractional inhibitory concentration (FIC index) by the checkerboard method. The 
active ingredients epicatechin (EC), epicatechin-3-gallate (ECG), epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG) present in the extract 
were quantitated by High Performance liquid Chromatography (HPLC).  
Results: AGTE exhibited significant antibacterial activity as the observed zones of inhibition ranged from 10–26 mm against the 44 ESBL producing 
E. coli strains. The MIC of AGTE was found to be in the range of 2.5-20 mg/ml with a mean of 7.23 mg/ml. 8 test strains showed synergism whereas 
the remaining showed an additive effect between AGTE and Cefotaxime. By HPLC analysis the concentration of EC, ECG, EGC, EGCG were found to be 
7.03, 10.08, 9.99 and 43.57 respectively, expressed as percentage w/w. 
Conclusion: As green tea extract has shown substantial antibacterial as well as synergistic activity, it can be of potential therapeutic value against 
ESBL producing Escherichia coli gastrointestinal infections.  
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INTRODUCTION 
Drug resistance is a natural step in microbial evolution, with many 
microorganisms, especially of the Enterobacteriaceae family being 
highly adaptable and easily capable of mutating to acquire means of 
exhibiting drug resistance. Since β-Lactam antibiotics are the most 
widely used, it is therefore not surprising that resistance to many β-
lactams is common and still evolving. Mechanisms of resistance to β-
lactams in Escherichia coli can be divided into three categories, 
namely, enzymatic inactivation of the antibiotic, alteration of the 
target, and reduced penetration of the antibiotic. Enzymatic 
inactivation to β-lactams is most often caused by the production of 
enzymes extended spectrum β-lactamases (ESBLs).  
Over the last 15 years, numerous outbreaks of infection with 
organisms producing ESBLs have been observed worldwide [1]. The 
advent of ESBLs producers has posed a great threat to the use of 
many classes of antibiotics particularly cephalosporins. There are 
indications that poor outcome occurs when patients with serious 
infections due to β-lactamase producing organisms are treated with 
antibiotics to which the organism is resistant [2].  
Extended spectrum Beta-lactamases (ESBL) hydrolyze extended 
spectrum cephalosporins and are inhibited by Clavulanic acid, 
Sulbactum and Tazobactum [3]. E. coli has been revealed to be one of 
the most commonly encountered ESBL producing organisms in 
various parts of India [4-6]. Treatment of such infections with a 
combination of a β-lactam with a β-lactamase inhibitor is common, 
but it may not always prevent the emergence of resistance [7]. 
 Several studies in the recent past emphasized the urgent need for 
new therapeutic strategies, including the use of plant extracts and 
phytochemicals extracted from them [8,9]. Such an approach can 
help curb or considerably decrease the occurrence of drug 
resistance among bacteria as plant extracts usually have multiple 
active ingredients that act at various target sites in the bacteria. 
Green tea (Camellia sinensis leaves) has been consumed since 
ancient times in China and has gained popularity in several other 
countries including India. Green tea extracts being a popular 
beverage consumed worldwide, inexpensive, and non-toxic, serves 
as a very important a source of alternative medicine. It is known to 
possess preventive activity against cardiovascular diseases and 
some forms of cancer [10]. Also, it has antioxidant [11], antitumor, anti-
inflammatory, anti diabetic, immunomodulatory [12] and antibacterial 
activities [8,9]. Green tea consists of catechins viz. epicatechin (EC), 
epicatechin-3-gallate (ECG), epigallocatechin (EGC), and 
epigallocatechin-3-gallate (EGCG). Other polyphenols include flavanols 
and their glycosides [13]. EGCG, a main constituent of green tea 
polyphenol, has been reported to have great antimicrobial activity and 
also exhibits synergistic properties with other antibiotics against Gram-
positive and Gram-negative bacteria [14-16]. By means of molecular 
dynamic simulations it was revealed that a number of tea catechins have 
a strong affinity for the lipid bilayer via hydrogen bonding to the lipid 
bilayer and among them EGCG showed the strongest interaction as it can 
form large number of hydrogen bonds.  
However the effect of Green tea for diarrhea causing ESBL producing E. 
coli still needs to be elucidated. The objective of the present study is thus 
to prepare an aqueous extract of Green tea and validate its antibacterial 
activity against diarrhea causing ESBL producing E. coli.  
MATERIALS AND METHODS 
The present study was carried out in the Department of 
Microbiology, Topiwala National Medical College and BYL Nair 
Charitable Hospital, Mumbai, India and approved by the local Ethics 
Committee of our institution. 
Bacterial strains  
E. coli strains were isolated and identified using standard methods 
from stool samples obtained from patients suffering with acute 
diarrhea admitted to our tertiary care hospital.  
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Determination of antimicrobial susceptibility 
Antimicrobial Susceptibility Testing (AST) was performed using the 
disk diffusion method as described by the Clinical and Laboratory 
Standard Institute (CLSI) using Kirby-Bauer method [18]. Antibiotic 
discs were obtained from Himedia Ltd. Antibiotics used were 
Chloramphenicol (C), Ciprofloxacin (Ci), Nalidixic acid (NA), 
Amoxyclav (AMC), Ceftriaxone (CTR), Ceftazidime (CAZ), Cefotaxime 
(CTX), Co-trimoxazole (CO) and Imipenem (I).  
Screening for ESBL production 
All the isolates showing resistance to 3rdgeneration cephalosporins, 
namely Ceftazdime, Ceftriaxone and Cefotaxime, were tested for 
confirmation of β-lactamase production by phenotypic confirmatory 
disc diffusion test (PCDDT). The Optical Density (O. D.) of the 
cultures were adjusted to 0.5 McFarland (∼1.5 × 108 CFUmL−1) and 
swabbed on Mueller-Hinton (MH) Agar plates. The screening was 
done as per CLSI guidelines [18]. 
Confirmation of ESBL production by E-test 
Confirmation of ESBL production was done using Multi-Ezy MICTM 
Strips (Hi-Media Laboratories Pvt. Ltd.). These strips differ from the 
conventional E-strips in that they contain a gradient of 3 antibiotics 
with and without Clavulanic acid on either side of the strip 
respectively instead of one antibiotic. The Multi-Ezy MICTM
The antibacterial activity of the extract was tested using the disk 
diffusion method described by the Clinical and Laboratory Standards 
Institute. Briefly, sterile paper discs (6 mm; Hi-Media, India) were 
loaded with 20 μl of extracts at concentration of 500 mg/ml 
dissolved in sterile distilled water and then left to dry for 18 h at 
37
 Strips 
contain Cefotaxime, Ceftazidime and Cefipime (MIX) on one side in a 
twofold gradient and the same antibiotics with Clavulanic acid 
(MIX+) on the other side. A ratio of inhibition zones for MIX and 
MIX+of ≥ 8 was considered as a positive E -test [19]. E. coli ATCC 
25922 as negative control and Klebsiella pneumonia ATCC 700603 as 
positive control were used in the test. 
Preparation of green tea extract 
The dried Green tea powder was provided by Konark Herbals and 
Health Care, Mumbai. 10 g of dried powder was boiled with 100 ml 
of distilled water for 10 min. The heated solution was filtered and 
evaporated at 40˚C. The aqueous green tea extract (AGTE) thus 
prepared was then kept in the refrigerator for further use. 
High-performance liquid chromatography analysis 
The High-performance liquid chromatography (HPLC) system 
consisted of a Shimadzu LC-2010CHT model (Shimadzu, Tokyo, 
Japan), with a column of Phenomenex Luna-C18 (4.6 × 250 mm, 5 
μm Merck) and detection at a wavelength of 280 nm. Elution was 
carried out at a flow rate of 1.6 ml/min under a linear gradient of 
Buffer made up of 0.136 g of anhydrous potassium dihydrogen 
phosphate in water and 0.5 ml of orthophosphoric acid (solvent A) 
and acetonitrile (solvent B), with a run time of 35 min. The AGTE 
was dissolved in water and 20 μl was injected into the HPLC. The 
presence of epicatechin (EC), epicatechin-3-gallate (ECG), 
epigallocatechin (EGC), and epigallocatechin-3-gallate (EGCG) was 
confirmed by the same retention time of their standards (Natural 
Remedies, India). The amount of catechins in the sample was 
calculated using the formula: 
Area of sample





weight of the sample (mg)
× Purity of the standard (%) 
Antibacterial activity of AGTE 
◦C. The bacterial suspensions were then diluted to a turbidity of 
approximately 0.5 McFarland (∼1.5 × 108 CFUmL−1). 
Ceftazidime/Clavulanic acid (30/10 µg) CAC and Imipenem (10 µg) 
(Hi-Media, India) was used as the positive control. After incubation 
at 37◦C for 24 h, the diameter of the zone of inhibition around each 
of the discs was measured and recorded. Each experiment was 
performed in triplicate. 
Determination of MIC 
The MIC value of the AGTE was determined using the Agar dilution 
technique [19]. The suspensions of all 44 ESBL producing E. coli 
cultures were adjusted to a turbidity of 0.5 McFarland. The AGTE 
was added to Mueller and Hinton agar in order to obtain 
concentrations from 0.05 % to 2 % (0.5 mg/ml to 20 mg/ml) and the 
plates were poured. Similarly plates containing Cefotaxime in the 
range of 5 to 1000μg/ml were prepared. Saline suspensions of the E. 
coli strains were inoculated onto the plates. The lowest 
concentration capable of inhibiting visible growth after 24 h of 
incubation at 37◦C was then recorded as the MIC. 
Determination of combined activity by Checkerboard assay 
Cefotaxime stock (10 mg/ml) and 10 % AGTE was used for the 
Checkerboard assay. The concentration range of Cefotaxime was 
from 5 to 1000 μg/ml and AGTE ranged from 0.05% to 2% (0.5 
mg/ml to 20 mg/ml). Visible growth after 24 h of incubation at 37◦
The antimicrobial effect of AGTE was determined using the disc 
diffusion method, carried out in triplicates. The average zone sizes 
ranged from 10–26 mm with a mean of 16 mm for the test strains. 
The individual zone sizes of the test strains are as shown in fig. 1. 
The MIC of AGTE was determined by the agar dilution technique. 
Concentrations from 0.05% to 2% (0.5 mg/ml to 20 mg/ml) were 
used to determine the MIC. MIC of AGTE for the 44 strains ranged 
from 2.5-20 mg/ml with a mean of 7.23 mg/ml as depicted in table 
2. As the organisms are all ESBL producers their MIC values for 
Cefotaxime were very high. A MIC of ≥ 4 µg/ml indicates ESBL 
production. As seen in table 3 all the 44 strains showed MIC of 
Cefotaxime ≥ 10 µg/ml hence clearly highlights the ESBL production 
of the test strains. 
C 
was checked and the MIC in combination for Cefotaxime and AGTE 
were determined for each strain of E. coli. The fractional inhibitory 
concentration was calculated as follows:  
FIC of compound a (FICa) = MIC of compound A (Cefotaxime) in 
combination/MIC of compound A alone 
FIC of compound b (FICb) = MIC of compound B (AGTE) in 
combination/MIC of compound B alone 
The sum of fractional inhibitory concentration (FICs) indices of two 
compounds in the combination was calculated as follows: FICa+FICb 
= FICs  
FIC indices were interpreted as synergic when values were ≤  0.5 
and as antagonistic when values were>4. The results between 
synergy and antagonistic tendency (>0.5 and<4) were defined as 
additive or indifferent. [20] 
RESULTS 
E. coli strains isolated from stool samples obtained from patients 
suffering from diarrhea were screened for their susceptibility to 
antibiotics Chloramphenicol (C), Ciprofloxacin (Ci), Nalidixic acid 
(NA), Amoxyclav (AMC), Ceftriaxone (CTR), Ceftazidime (CAZ), 
Cefotaxime(CTX), Co-trimoxazole (CO) and Imipenem (I). The 
susceptibility pattern of the test strains is as shown in table 1. All the 
strains were resistant to Ampicillin, Ceftriaxone, Ceftazidime, 
Cefotaxime and Nalidixic acid. 57% of the strains exhibited 
resistance towards Amoxyclav, 66% each towards Co-trimoxazole 
and Ciprofloxacin. 61% were resistant to Chloramphenicol whereas 
all were sensitive to Imipenem as observed in table 1. Resistance to 
all the third generation Cephalosporins viz. Ceftriaxone, Ceftazidime, 
Cefotaxime indicates that the stains are ESBL producers, which was 
confirmed by PCDDT and E-test. The Phenotypic confirmatory disc 
diffusion test was positive for all the E. coli strains as an increase in 
the zone diameter for Ceftazidime-Clavulanic acid by ≥ 5 mm as 
compared to Ceftazidime alone was observed. E-test using Ezy-
MICTM strips confirmed the ESBL production of all the 44 E. coli 
strains as a ratio of inhibition zones for MIX and MIX+of ≥ 8 was 
observed. To estimate the amounts of active ingredients EC, ECG, EGC, 
and EGCG, HPLC analysis was carried out and were found to be 7.03, 
10.08, 9.99 and 43.57 respectively, expressed as percentage w/w. EGCG 
being the main catechin is present in maximum amount in AGTE. 
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Table 1: Pattern of Antibiotic susceptibility of the E. coli strains 
Antibiotic  A AMC C Co Ci NA CAZ CTX CTR I 
 No. of strains resistant 44  25  27  29  29  44  44  44  44  0  
Percentage of resistant strains 100 57 61 66 66 100 100 100 100 0 
Note: n = 44 
 
Table 2: MIC of AGTE against ESBL producing E. coli. Table shows number and percentage of strains inhibited by various concentrations of AGTE 
Concentration of AGTE (mg/ml) 0.5 1.0 2.5 5.0 10 15 20 25 
No. of strains inhibited - - 13 8 21 - 2 - 
Percentage of strains inhibited - - 29.5 18.2 47.7 - 4.5 - 
Note: n = 44 
 
Table 3: MIC of Cefotaxime against ESBL producing E. coli. Table shows number and percentage of strains inhibited by various 
concentrations of Cefotaxime 
Concentration of Cefotaxime (µg/ml) 10 50 100 150 200 250 300 350 500 1000 
No. of strains inhibited 4 4 7 6 3 2 9 3 - 6 
Percentage of strains inhibited 9.1 9.1 15.9 13.6 6.8 4.5 20.5 6.8 0 13.6 
Note: n = 44 
 
The combined activity of Cefotaxime and AGTE was determined by 
checkerboard assay. Calculations of FICs were performed as shown 
below for strain E8 as an example as shown in fig. 2. For strain E8, 
FIC a = 50/350 = 0.14. FIC b = 2.5/10 =0.25 
So FICs = 0.14+0.25 = 0.39 rounded up to 0.4, which indicates a 
synergistic effect between Cefotaxime and AGTE. The results 
obtained for all the 44 strains are as mentioned in table 4 where 8 
strains are showing synergistic activity with FICs ≤ 0.5, whereas all 
the remaining strains showed an additive effect with FICs between 




Fig. 1: Bar chart showing mean zone sizes of AGTE by disc 
diffusion method. Vertical bars indicate standard deviation (n=3) 
 
 
Fig. 2: Interpretation of combined effect of AGTE and 
Cefotaxime by Checkerboard assay for strain E8 
DISCUSSION 
For the last several years, frequent occurrence of infection with 
organisms producing β-lactamases has been observed globally [21]. 
The advent of β-lactamases producers has established a great hazard 
to the use of many classes of antibiotics particularly cephalosporins. 
There are indications that poor outcome arises when patients with 
severe infections due to β-lactamase producing organisms are 
treated with antibiotics to which the organism is resistant [2]. The 
high incidence of gastrointestinal tract infections in the general 
population, the potential for complications, especially in developing 
countries like India and the associated costs of treatments calls attention 
to the importance of alternate therapy. In this regard plant extracts are 
being comprehensively researched by scientists [15, 22, 23].  
E. coli strains were isolated from patients suffering from severe 
diarrhea. Resistance to antimicrobial agents in these species has 
become an increasingly relevant problem for health care providers. 
These isolates were confirmed to be ESBL producers by PCDDT and 
E test. Due to ESBL production these organisms were resistant to 
third generation cephalosporins. Their resistance was also extended to 
other groups of antibiotics like Ciprofloxacin and Co-trimoxazole. Many 
times ESBL producing organisms posses or have acquired genes that 
encode co-resistance to two or more groups of antibiotics. Management 
and treatment of infections caused by such resistance pathogens offer a 
great difficulty and increase health care cost. Therefore, there is a need to 
investigate alternate methods of therapy. 
Green tea is consumed worldwide now and its beneficial 
physiological and pharmacological effects are very well known. A 
study by Nima et al. [24] stated the MIC of aqueous green tea for 18 
E. coli isolates to be in the range of 75 to 150 mg/ml with a mean of 
122 mg/ml. In another study by Tiwari et al. [16] the MIC of green 
tea extract against E. coli was found to be 88.30 mg/ml. In this study 
the MIC values ranged from 2.5-20 mg/ml with a mean of 7.23 
mg/ml which is much lesser than the previous study suggesting 
better extraction of tea catechins. There are various studies that 
have carried out in vivo experiments to demonstrate the significance 
of Green tea. One such study by Toda et al. [25] proved that a 
mixture of tea catechins protected rabbits from an experimental 
infection caused by V. cholerae and suggested that patients with 
cholera could benefit if tea extracts were added to oral rehydration 
solutions.  
Antibiotic therapy combined with phytochemicals may delay the 
emergency of bacterial resistance and may also produce desirable 
synergistic effects in the treatment of infections caused by ESBL 
producing organisms. This could be due to the fact that crude plant 
extracts have many different phytochemicals, which inhibit bacteria 
by different unknown mechanisms. This dual attack of both 
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could lead to either an additive or a synergistic effect. AGTE showed a 
decrease in the MIC of Cefotaxime for all the test strains. 8 strains 
showed synergism whereas the remaining test strains showed an 
additive effect. None of the test strains showed antagonistic effect 
between AGTE and Cefotaxime. Such synergistic activity was also 
demonstrated by Cui Y. et al. in 2012 [15], Tiwari et al. in 2004 [16] 
and Zhi-Qing Hu et al. in 2002 [20] on different test organisms. Hence 
there is no doubt about Green tea being a boon, antimicrobial benefit 
of which should be reaped in the form of providing lead molecules in 
developing better and effective drugs by pharmacists. 
 
Table 4: FIC values and results of combined effect of Cefotaxime and AGTE against ESBL producing E. coli 
Strain No. FICs Effect Strain no FICs Effect 
E1 2.9 A E23 0.6 A 
E2 0.1 S E24 0.6 A 
E3 1.3 S E25 1.5 A 
E4 2.0 A E26 2.3 A 
E5 0.8 A E27 2.1 A 
E6 0.8 A E28 2.8 A 
E7 2.5 A E29 1.6 A 
 E8 0.4 S E30 2.5 A 
E9 0.9 A E31 0.2 S 
E10 2.0 A E32 0.3 S 
E11 2.1 A E33 2.0 A 
E12 2.5 A E34 1.7 A 
E13 0.3 S E35 1.3 A 
E14 1.5 A E36 0.8 A 
E15 1.5 A E37 1.7 A 
E16 1.8 A E38 0.8 A 
E17 0.4 S E39 1.7 A 
E18 1.0 A E40 1.0 S 
E19 1.3 A E41 0.6 A 
E20 1.5 A E42 0.8 A 
E21 0.6 A E43 2.5 A 
E22 1.7 A E44 1.6 A 
Note: S means Synergistic effect as FICs ≤ 0.5, A means Additive effect with FICs between 0.5 and 4 
 
CONCLUSION 
Green tea (Camellia sinensis) extract has been proved to be effective 
against ESBL producing E. coli not only alone but also in combination 
with antibiotic. The tea catechins can be purified and tested further in 
vivo which will help to confirm the therapeutic value of Green tea. 
Thus, Green tea can be used as an alternate therapy or can be used as 
an addition to the existing conventional therapy to cure diarrheagenic 
infections caused by ESBL producing E. coli. 
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